Novo Nordisk seeks EU and U.S. approval for new diabetes treatment

News Hour:

Danish Novo Nordisk said on Monday it has filed for the European Union and the U.S. approval of semaglutide to treat adults with type 2 diabetes, reports Reuters.

The company said the results of the clinical trial, which included more than 8,000 adults with type 2 diabetes, demonstrated statistically significant and sustained blood glucose control, and a statistically significant reduction of cardiovascular risk compared to placebo.


This article has been posted by a News Hour Correspondent. For queries, please contact through [email protected]
No Comments

Join Epidemiology Congress 2019

Translate this News

Join the Facebook Group

Click here to join the Facebook group of News Hour

Popular Posts


News of the Month

Scroll Up
%d bloggers like this: